41639-83-2 | Latanoprost acid

75-30-9    41639-83-2    130209-82-4 

[1]Hayashi,Yujiro;Umekubo,Nariyoshi[EuropeanJournalofOrganicChemistry,2020,vol.2020,#39,p.6221-6227]

[2]Locationinpatent:experimentalpartZanoni,Giuseppe;D'Alfonso,Alessandro;Porta,Alessio;Feliciani,Lazzaro;Nolan,StevenP.;Vidari,Giovanni[Tetrahedron,2010,vol.66,#38,p.7472-7478]

[3]CurrentPatentAssignee:EUROAPIHUNGARYLIABILITYCOMPANY-WO2015/136317,2015,A1Locationinpatent:Page/Pagecolumn17

[4]CurrentPatentAssignee:ABBVIEINC-WO2013/186550,2013,A1Locationinpatent:Page/Pagecolumn97;98

[5]Prévost,Sébastien;Thai,Karen;Schützenmeister,Nina;Coulthard,Graeme;Erb,William;Aggarwal,VarinderK.[OrganicLetters,2015,vol.17,#3,p.504-507]

[6]CurrentPatentAssignee:ABBVIEINC-US2015/158837,2015,A1Locationinpatent:Paragraph0490-0496

[7]Zhu,Kejie;Hu,Sha;Liu,Minjie;Peng,Haihui;Chen,Fen-Er[AngewandteChemie-InternationalEdition,2019,vol.58,#29,p.9923-9927][Angew.Chem.,2019,vol.131,#29,p.10028-10032,5]

[8]Resul,Bahram;Stjernschantz,Johan;No,Kiyo;Liljebris,Charlotta;Selen,Goeran;etal.[JournalofMedicinalChemistry,1993,vol.36,#2,p.243-248]

[9]CurrentPatentAssignee:PFIZERINC-US2003/187071,2003,A1

[10]CurrentPatentAssignee:NOVARTISAG;Sandoz(in:Novartis)-EP2143712,2010,A1Locationinpatent:Page/Pagecolumn55-56

[11]CurrentPatentAssignee:TECHNOPHARMA-EP1721894,2006,A1Locationinpatent:Page/Pagecolumn4;16;19;22

[12]CurrentPatentAssignee:ZHEJIANGXIANJUPHARMACEUTICALCOMPANYLIMITED-EP2495235,2012,A1Locationinpatent:Page/Pagecolumn24-25

[13]CurrentPatentAssignee:CHIROGATEINTERNATIONAL,INC.-EP2837621,2015,A1Locationinpatent:Paragraph0174;0175;0176;0177;0178

[14]CurrentPatentAssignee:CHIROGATEINTERNATIONAL,INC.-US2015/51410,2015,A1Locationinpatent:Paragraph0174;0175;0176;0177

[15]CurrentPatentAssignee:SHANGHAITECHWELLBIOPHARMACEUTICALCO.,LTD-CN106467465,2017,ALocationinpatent:Paragraph0090;0091;0092;0094;0095;0098;0101;0108

75-30-9    41639-83-2   

isopropyl(E)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-(R)-3-hydroxy-5-phenylpentylcyclopentyl}hept-5-enoate 

  130209-82-4 

[1]Martynow,JacekG.;Jozwik,Julita;Szelejewski,Wieslaw;Achmatowicz,Osman;Kutner,Andrzej;Wisniewski,Krzysztof;Winiarski,Jerzy;Zegrocka-Stendel,Oliwia;Golebiewski,Piotr[EuropeanJournalofOrganicChemistry,2007,#4,p.689-703]

31752-99-5    41639-83-2 

[1]JournalofMedicinalChemistry,1993,vol.36,p.243-248

71831-21-5    41639-83-2    860006-34-4 

[1]Patent:WO2005/68421,2005,A1.Locationinpatent:Page/Pagecolumn41-42

41639-83-2    130209-82-4 

[1]CurrentPatentAssignee:SHENZHENCATALYSTECH;KAETELLISSHENZHENSCIENCEANDTECHCOLTD-WO2022/57734,2022,A1Locationinpatent:Page/Pagecolumn17-18

[2]CurrentPatentAssignee:PFIZERINC-US2003/45571,2003,A1

Title: Discovery of 13-oxa prostaglandin analogs as antiglaucoma agents: synthesis and biological activity.

Journal: Bioorganic & medicinal chemistry 20090115

Title: Comparison between isopropyl unoprostone and latanoprost by prostaglandin E(2)induction, affinity to prostaglandin transporter, and intraocular metabolism.

Journal: Experimental eye research 20020101

Title: Increased human scleral permeability with prostaglandin exposure.

Journal: Investigative ophthalmology & visual science 20010601

Title: Latanoprost and matrix metalloproteinase-1 in human choroid organ cultures.

Journal: Current eye research 20010301

Title: The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.

Journal: Biochimica et biophysica acta 20000117